Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein. [ ]
Term info
Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
- Anti-MART-1 TCR Retroviral Vector-Transduced Autologous PBL
- Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
- MSGV1AIB (Anti-MART-1 TCR) Retroviral Vector-Transduced Autologous PBL
NCIT_C116978, NCIT_C128784, NCIT_C116977
CTRP
Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
http://purl.obolibrary.org/obo/NCIT_C28724
Anti-MART-1_TCR_Retroviral_Vector-Transduced_Autologous_PBL
CL322828
729279
560192
560192
Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
Pharmacologic Substance, Cell
C38587
Term relations
- T-cell Receptor-engineered T-cells
- Antineoplastic Immune Cell
- Therapeutic Autologous Lymphocytes
- Chemical_Or_Drug_Has_Physiologic_Effect some T-Cell Activation
- Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some Cytotoxic T-Lymphocyte
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Antigen Sensitization
- Chemical_Or_Drug_Has_Physiologic_Effect some Immunopotentiation